HK1104533A1 - Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both - Google Patents

Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both

Info

Publication number
HK1104533A1
HK1104533A1 HK07109656.9A HK07109656A HK1104533A1 HK 1104533 A1 HK1104533 A1 HK 1104533A1 HK 07109656 A HK07109656 A HK 07109656A HK 1104533 A1 HK1104533 A1 HK 1104533A1
Authority
HK
Hong Kong
Prior art keywords
receptor
benzodioxanes
arylsulfonyl
modulating
useful
Prior art date
Application number
HK07109656.9A
Other languages
English (en)
Inventor
Jacob Berger
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1104533A1 publication Critical patent/HK1104533A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
HK07109656.9A 2004-05-05 2007-09-05 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both HK1104533A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56831404P 2004-05-05 2004-05-05
PCT/EP2005/004479 WO2005105776A1 (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both

Publications (1)

Publication Number Publication Date
HK1104533A1 true HK1104533A1 (en) 2008-01-18

Family

ID=34965191

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109656.9A HK1104533A1 (en) 2004-05-05 2007-09-05 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both

Country Status (21)

Country Link
US (1) US7368567B2 (de)
EP (1) EP1748995B1 (de)
JP (1) JP2007536302A (de)
KR (1) KR100823805B1 (de)
CN (1) CN100540546C (de)
AR (1) AR048936A1 (de)
AT (1) ATE458727T1 (de)
AU (1) AU2005238179B2 (de)
BR (1) BRPI0510642A (de)
CA (1) CA2566196A1 (de)
DE (1) DE602005019562D1 (de)
ES (1) ES2338668T3 (de)
HK (1) HK1104533A1 (de)
IL (1) IL178819A0 (de)
MX (1) MXPA06012621A (de)
NO (1) NO20065510L (de)
NZ (1) NZ550441A (de)
RU (1) RU2372344C2 (de)
TW (1) TWI298636B (de)
WO (1) WO2005105776A1 (de)
ZA (1) ZA200608588B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031338B (zh) * 2004-09-30 2013-01-02 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
CA2591810A1 (en) * 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
GT200600159A (es) * 2005-04-22 2007-03-14 Derivados benzodioxano y benzodioxolano y usos de los mismos
ES2359735T3 (es) 2005-11-03 2011-05-26 F. Hoffmann-La Roche Ag Arilsulfonilcromanos como inhibidores de 5-ht6.
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
BRPI0713742A2 (pt) 2006-06-20 2013-02-13 Hoffmann La Roche derivados de arilsulfonila naftaleno e usos destes
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
CA2722978A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
DK2271638T3 (da) 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
CN114890978B (zh) * 2022-04-19 2023-07-25 宿迁医美科技有限公司 酚类化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
TW224941B (de) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5506192A (en) 1990-06-07 1996-04-09 Sandoz Ltd. Substituted phthalides and heterocyclic phthalides
JP3210665B2 (ja) 1990-07-27 2001-09-17 中外製薬株式会社 新規なベンゾピラン誘導体
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5817693A (en) 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
ZA93436B (en) 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
AU4761693A (en) 1992-08-17 1994-03-15 Chugai Seiyaku Kabushiki Kaisha Benzopyran and benzoxazine derivatives
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5869478A (en) 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
PL324319A1 (en) 1995-06-30 1998-05-25 Upjohn Co 1,6-disubstituted isochromates for fighting against sick headaches
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US6214881B1 (en) 1996-08-21 2001-04-10 Smithkline Beecham Corporation IL-8 receptor antagonists
US6559144B2 (en) 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
PT971878E (pt) 1997-02-27 2008-07-08 Takeda Pharmaceutical Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HU226652B1 (en) 1998-12-04 2009-05-28 Takeda Pharmaceutical Benzofuran derivatives, process for preparation of the same and uses thereof
ES2312423T3 (es) 2000-04-03 2009-03-01 Takeda Pharmaceutical Company Limited Procedimiento para producir derivados de amina.
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
MXPA04003087A (es) 2001-10-04 2004-09-06 Wyeth Corp Derivados de cromano como ligados de 5-hidroxitriptamina-6.
MXPA04011254A (es) * 2002-05-13 2005-01-25 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-hidroxitriptamina 6 (5-ht6) y usos de los mismos.
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
US7795242B2 (en) 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use

Also Published As

Publication number Publication date
TWI298636B (en) 2008-07-11
AR048936A1 (es) 2006-06-14
MXPA06012621A (es) 2006-12-15
AU2005238179B2 (en) 2010-08-26
BRPI0510642A (pt) 2007-11-20
NZ550441A (en) 2009-07-31
NO20065510L (no) 2007-01-12
TW200605894A (en) 2006-02-16
CN100540546C (zh) 2009-09-16
RU2372344C2 (ru) 2009-11-10
DE602005019562D1 (de) 2010-04-08
WO2005105776A8 (en) 2007-01-11
ZA200608588B (en) 2008-06-25
KR100823805B1 (ko) 2008-04-21
US20050250943A1 (en) 2005-11-10
IL178819A0 (en) 2007-03-08
US7368567B2 (en) 2008-05-06
ATE458727T1 (de) 2010-03-15
CA2566196A1 (en) 2005-11-10
AU2005238179A1 (en) 2005-11-10
CN1960983A (zh) 2007-05-09
EP1748995B1 (de) 2010-02-24
ES2338668T3 (es) 2010-05-11
RU2006138180A (ru) 2008-06-10
JP2007536302A (ja) 2007-12-13
EP1748995A1 (de) 2007-02-07
WO2005105776A1 (en) 2005-11-10
KR20070009664A (ko) 2007-01-18

Similar Documents

Publication Publication Date Title
HK1104533A1 (en) Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both
IL187099A0 (en) Novel 8-sulfonylamino - 3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
AP2403A (en) Histamine-3 receptor antagonists.
EG25344A (en) Substituted morpholine and thiomorpholine derivatives.
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
PL374229A1 (en) Indole or benzimidazole derivatives for modulating ik b kinase
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
HK1095329A1 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
DE602004026241D1 (de) Prothese für das Schultergelenk.
ZA200409339B (en) Novel benzimidazole derivatives.
HK1111698A1 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
ZA200705040B (en) 2,4 (4,6) pyrimidine derivatives
DE602004010791D1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
IL178086A0 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
IL177059A0 (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists
IL190608A0 (en) 5-(arylsulfonyl)-pyrazolopiperidines
AU2005234596A8 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ZA200800213B (en) Benzimidazole derivatives as 5-HT6, 5-HT24
DE602004014773D1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
HK1063969A2 (en) Reaming aiguille.
ZA200709728B (en) Novel 8-sulfonyl-3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5HT6 receptor
FI20031321A (fi) Sakeuslähetin
IL187095A0 (en) Novel 8 - sulfonyl - 3 aminosubstituted chroman or tetrahydronaphtalene derivatives modulating the 5ht6 receptor
ZA200606563B (en) 3-Substituted 1,5-diphenylpyrazole derivatives useful as CB1 Modulators

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM F. HOFFMANN-LA ROCHE TO F. HOFFMANN-LA ROCHE AG

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140427